Navigation Links
50 Pharma Companies Worldwide Now Use Codexis In Process Development
Date:10/24/2011

FRANKFURT, Germany, Oct. 24, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that one year after launch, its Codex® Screening Kits are in use or evaluation in manufacturing process development at 50 pharmaceutical companies worldwide.  The announcement was made at CPhI  Worldwide, a global pharmaceutical ingredients convention meeting here this week.  

Codex® Screening Kits were introduced in October 2010.  Pharmaceutical and fine chemical companies including Merck, Roche, DSM and Dainippon Sumitomo are among the global customers using Codex® Screening Kits and Codex® Panels to reduce pharmaceutical manufacturing process development time and cost.  

Codexis also said that through September 30, 2011, more than 10,000 kilograms of various enzymes used in commercial pharmaceutical intermediates production processes have been manufactured by the company's enzyme production partners. Smaller 10-100 kilogram quantities, also used in processes to make commercial pharmaceutical intermediates, have been manufactured at its Redwood City, CA facility.

"With a global network of production capabilities established, we are supporting our pharmaceutical and fine chemical customers at every scale, from clinical development to commercial production.  This further demonstrates the utility of Codexis biocatalyst enzymes for the development and commercial production of pharmaceutical products," said Peter Strumph, Senior Vice President and Business Head, Pharmaceuticals.

Codexis is an industrial biotechnology company developing products that make manufacturing processes faster, cleaner and cheaper. Codexis' technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell and for biobased chemicals.  For more information, visit www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the utility of Codexis' biocatalyst enzymes for the development and commercial production of pharmaceutical products. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Important factors known to Codexis that could materially affect actual results include Codexis' dependence on contract manufacturers for commercial scale production of its biocatalysts.  Other factors can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:  
Media:  Lyn Christenson, lyn.christenson@codexis.com, 650.421.8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212.827.3771   Investors:  Henk Adriaenssens, ir@codexis.com, 650.421.8331


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. S1 Pharmaceuticals Appoints Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to Its Scientific Advisory Board
2. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
3. Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
4. Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company
5. Cumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloittes 2011 Technology Fast 500™
6. Onyx Pharmaceuticals Announces Third Quarter 2011 Financial Results Teleconference and Webcast
7. Jazz Pharmaceuticals Announces Third Quarter 2011 Results Conference Call on November 1
8. Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
9. Study Finds Children More Likely to Receive Recommended RSV Medication Doses When Administered Through Specialty Pharmacy
10. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
11. Academy of Managed Care Pharmacy Opens 2011 Educational Conference in Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA ... Training Institute Education Center headquartered in Northern California, has issued an important reminder ... at their worksites. Employers with workers exposed to high temperatures should establish ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... "FCPX editors ... customizable inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... style. Final Cut Pro X users can now reveal the media of ...
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
Breaking Medicine News(10 mins):